Clinical Trials Sponsored by Prevencion

Total 1750 results

Prevencion

Unknown

INTERVENCION Trial (INTERVENCION)

Blood Pressure, High

Peru
Colorado Prevention Center

Completed

Implementation of Vascular Care Team to Improve Medical Management of PAD Patients

Peripheral Artery Disease

United States
113 Suicide Prevention

Completed

Breaking Down Barriers to a Suicide Prevention Helpline

Suicidal Ideation

Netherlands
Prevention Strategies, LLC

Completed

Implementation of a Web-based Alcohol and Other Drug Prevention Intervention for Collegiate Student-athletes

Alcohol Drinking | Harm Reduction | Social Norms | Expectations
Real Prevention, LLC

Completed

REAL Parenting Alcohol and Substance Use App (RP)

Underage Drinking | Alcohol Use, Underage

United States
Real Prevention, LLC

Withdrawn

Peer-to-peer Tobacco and ENDS Prevention (PPSM)

Substance Use

United States
Colorado Prevention Center

Withdrawn

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Peripheral Arterial Disease | Angina

United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

COVID-19 Prevention

United States, South Africa, Brazil
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (HORIZON 2)

Coronavirus Disease-2019 (COVID-19) Prevention

South Africa, Brazil, Argentina, Mexico, India
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

HIV-1

South Africa, Malawi, Mozambique, Zambia, Zimbabwe
HIV Prevention Trials Network

Completed

Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection

Acute HIV Infection

Malawi
HIV Prevention Trials Network

Completed

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers (HPTN066)

HIV

United States
HIV Prevention Trials Network

Completed

Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings (HPTN063)

HIV

Brazil, Thailand, Zambia
Janssen Vaccines & Prevention B.V.

Completed

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Human Immunodeficiency Virus

Thailand
COVID-19 Prevention Network

Completed

SARS-CoV-2/COVID-19 Prevalence Study

COVID-19

United States, Puerto Rico
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

Healthy

Philippines
Janssen Vaccines & Prevention B.V.

Completed

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Healthy

United States
Amgen
Colorado Prevention Center

Recruiting

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction (EVOLVE-MI)

Myocardial Infarction | Stroke | Cardiovascular Disease | Coronary Revascularization

United States, Brazil, Sweden
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older (EVERGREEN)

Respiratory Syncytial Viruses | Lower Respiratory Tract Disease

United States, Taiwan, Thailand, Canada, Poland, United Kingdom, Brazil, Chile, New Zealand, Estonia, Finland, South Africa, Australia, China
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

United States, Mexico, South Africa, Brazil, Chile, Colombia, Peru, Argentina
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 (Amplify)

Coronavirus Disease

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

Respiratory Syncytial Virus Infection Prevention

Germany, Spain, Belgium, Sweden, United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Healthy

United States, Rwanda
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Respiratory Tract Infections | Respiratory Syncytial Viruses

United Kingdom, Finland, United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents

Healthy

United Kingdom, Germany, Spain, Netherlands
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Covid-19 Prevention

Belgium, United States
HIV Prevention Trials Network

Completed

A Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in Zambia

HIV Infections

Zambia
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Healthy

Netherlands
Cancer Prevention Pharmaceuticals, Inc.

Completed

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis

United States, Belgium, Germany, Canada, Netherlands, Spain, United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Healthy

Belgium
Janssen Vaccines & Prevention B.V.

Completed

A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

Healthy

Belgium
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Cancer Prevention Pharmaceuticals, Inc.

Withdrawn

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis
Janssen Vaccines & Prevention B.V.

Active, not recruiting

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (CYPRESS)

Respiratory Tract Diseases | Respiratory Syncytial Viruses

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa

3

Subscribe